W1M Asset Management Ltd Takes Position in Arrowhead Pharmaceuticals, Inc. $ARWR

W1M Asset Management Ltd bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 2nd quarter, Holdings Channel.com reports. The firm bought 10,700 shares of the biotechnology company’s stock, valued at approximately $873,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its position in shares of Arrowhead Pharmaceuticals by 243.8% in the second quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company’s stock worth $16,459,000 after buying an additional 143,192 shares in the last quarter. Siren L.L.C. raised its holdings in shares of Arrowhead Pharmaceuticals by 7.7% during the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after acquiring an additional 115,000 shares in the last quarter. Kornitzer Capital Management Inc. KS purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $2,375,000. Baader Bank Aktiengesellschaft bought a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $912,000. Finally, SBI Okasan Asset Management Co.Ltd. bought a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $2,541,000. Institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling

In related news, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director directly owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on ARWR. HC Wainwright increased their price target on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective for the company. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Royal Bank Of Canada upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $97.33.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $87.11 on Friday. The company has a market capitalization of $12.27 billion, a price-to-earnings ratio of -38.72 and a beta of 1.27. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.44 and a 12-month high of $95.49. The business’s fifty day simple moving average is $82.84 and its 200-day simple moving average is $72.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. During the same quarter in the previous year, the company earned ($1.26) earnings per share. The firm’s revenue was up 171.0% on a year-over-year basis. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.